Glaukos Corporation (GKOS) Stock Price, News, Analysis | DailyIQ

|

Technical Score (1D)

41

BEARISH

News Sentiment

49

MIXED

The 1D score for Glaukos Corporation (GKOS) is 41, with a NEUTRAL lean and weakening momentum. The price structure is compressed and neither trend indicators nor sentiment are offering a strong directional read right now. Sentiment at 49 is diverging from the flat technical backdrop - the two are essentially in sync, but both are pointing to indecision rather than conviction. Trying to get ahead of the direction in conditions like this tends to produce more frustration than results. Traders should watch for a breakout from the $157.98 to $171.14 range, treating either extreme as a potential trigger. Patience at this stage typically outperforms forcing a trade. The longer GKOS sits between $157.98 and $171.14 without resolving, the more energy tends to build for whichever direction eventually wins out. That's not a reason to anticipate the break - it's a reason to have orders ready on both sides so the reaction, whenever it comes, doesn't get missed entirely.

GKOS|Analyst Targets

LOW TARGET

$172 +6.4%

2 analysts

MEAN TARGET

$199 +23.0%

7 analysts

HIGH TARGET

$225 +39.2%

13 analysts

PRICE RANGE

$172.00 - $225.00

SB / B / H / S / SS

8/10/2/1/1

DAILYIQ EST.

$204.12 (+26.3%)

GKOS|Insider Trading

Bought (1Y)

0 shares

$0

Sold (1Y)

137,692 shares

$23.7M

Navratil TomasCHIEF DEVELOPMENT OFFICER

Sell1,083 shares2026-09-25

Navratil TomasCHIEF DEVELOPMENT OFFICER

Sell229 shares2026-09-25

Navratil TomasCHIEF DEVELOPMENT OFFICER

Sell136 shares2026-09-25

Navratil TomasCHIEF DEVELOPMENT OFFICER

Sell167 shares2026-09-25

Navratil TomasCHIEF DEVELOPMENT OFFICER

Sell4 shares2026-09-16

GKOS|Fundamentals

Neutral / mixed

Overall: Neutral

✓Revenue growing year over year

✕Negative net margin

✕Negative operating cash flow

Gross Margin

55.7%

Net Margin

-37.0%

Revenue CAGR

30.4%

Current Ratio

4.69x

Debt / Equity

0.01x

Return on Equity

-28.6%

GKOS|Earnings Snapshot

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$-0.09	-	-
Q3'25	$-0.26	$-0.16	+38.9%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$171M	-	-
Q3'25	-	$134M	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

GKOS|Monthly Returns

Market Data

GKOS Stock Snapshot

NEUTRAL41/100

$161.59−$0.10 (0.1%)

Market cap: 9.66B
Day range: $160.30 – $166.30
News sentiment: 49/100 · Neutral
Analyst target: $198.69 (+23.0%)
Consensus: Buy · 22 analysts

52-week range+120.9% off low · -15.7% from high

$73.16$191.62

Price $161.59 DailyIQ Est. $204.12

The technical read on GKOS is balanced, which usually means the market is waiting on a catalyst. Thinner liquidity means moves can extend past what the fundamentals alone justify.

Behaviour On Record

What GKOS's own history says about today's numbers

Realized volatility (21d): 39.6% 40th pct
Below its peak: -13.4%
vs 200-day average: +21.4%
Up days (1y): 49%

Glaukos Corporation is currently running 39.6% annualised volatility over the last 21 sessions. Measured against GKOS's own 11 years of daily returns rather than a market-wide average, that is the 40th percentile — on the quiet side for this stock, against a typical reading of 43.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

GKOS is trading -13.4% below its running peak. Across 10 full years on file, its median worst-drawdown-in-a-year was -43.2%, and the deepest was -63.6% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +21.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 64th percentile — a somewhat wider gap than its own norm. Over the past year GKOS closed higher on 49% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 11 years of records, GKOS finished the month higher 6 of 11 times, with a median return of +2.9% and an average of -0.3%. Its strongest month historically has been June at +12.3% on average, its weakest March at -4.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: GKOS has opened more than 2% away from the prior close in 243 of 2,835 sessions (8.6% of the time), with the largest gaps running +20.6% and -21.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 2,836 daily closes between 2015-06-25 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against GKOS's own 11-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of GKOS's sector?

Glaukos Corporation sits in the Health Care sector, currently ranked 8th of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank: #8 of 12
Sector state: Lagging
Sector rotation score: 0

Options Market

What is the options market pricing for GKOS?

CallsPuts

For Glaukos Corporation's nearest expiry (2026-10-16, 10 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 1.76), with at-the-money implied volatility around 60.4%. The options market is pricing roughly a ±9.7% move by that expiry — a range of about $143.18–$173.92.

Put/call ratio (2026-10-16): 1.76
ATM implied volatility: 60.4%
Total open interest: 8,480
Expected move by 2026-10-16: ±9.7% ($143.18–$173.92)

Analyst Rating Changes

Are analysts turning bullish or bearish on GKOS?

Jefferies most recently reiterated its rating on Glaukos Corporation to Buy on Sep 22, 2026 with a price target of $210 (from $190). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action: Jefferies — Buy
90-day upgrades: 0
90-day downgrades: 0
Net rating momentum: 0

Date	Firm	Action	Rating	Price target
Sep 22, 2026	Jefferies	Maintained	Buy	$190 → $210
Aug 20, 2026	BTIG	Maintained	Buy	$193 → $202
Jul 30, 2026	UBS	Maintained	Neutral	$150 → $172
Jul 30, 2026	HC Wainwright & Co.	Maintained	Buy	$168 → $195
Jul 30, 2026	Citigroup	Maintained	Buy	$175 → $188
Jul 30, 2026	Piper Sandler	Reiterated	Overweight	$165 → $195
Jul 30, 2026	Jefferies	Maintained	Buy	$165 → $190
Jul 30, 2026	Stifel	Maintained	Buy	$175 → $190
Jul 30, 2026	Truist Securities	Maintained	Buy	$180 → $215
Jul 30, 2026	Wells Fargo	Maintained	Overweight	$138 → $178
Jul 30, 2026	Needham	Maintained	Buy	$150 → $201
Jul 30, 2026	BTIG	Maintained	Buy	$164 → $193

Held by These ETFs

GKOS is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.

News Sentiment Analysis

Sentiment gathered from recent headlines

49/100

Strong NegativeNeutralStrong Positive

MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Glaukos (GKOS) achieved an average annual return of 14.97% over the past decade, outperforming the broader market by 1.4% on an annualized basis. The company’s market capitalization stands at $9.57 billion. This performance demonstrates sustained growth and investor confidence in Glaukos’ product pipeline and market positioning.

What did this article say?

Glaukos Corporation has launched the "Could it be KC?" campaign in partnership with NBA star Stephen Curry to raise awareness of keratoconus. The initiative aims to educate patients, families, and clinicians about early detection and diagnosis of this rare, sight‑threatening corneal disorder. While the campaign does not directly impact product sales, it positions Glaukos as a proactive advocate for patient education, potentially improving market perception and early adoption of its therapies. The partnership may generate media coverage and strengthen relationships with eye care providers, but it carries limited immediate financial upside.

What did this article say?

Glaukos’ recent share rally has raised questions about whether the current $159.86 price reflects its sales trajectory. Analysts note the company’s strong long‑term gains but highlight that the business remains loss‑making, making a revenue multiple assessment critical. The debate centers on whether future ophthalmology procedure adoption can justify a higher valuation, or if the market has already priced in the growth potential.

What did this article say?

Glaukos (GKOS) experienced a 1% decline, extending a 14% month‑long pullback, while its annual revenue of $612.8 million remains solid. The stock’s short‑term performance has cooled, with a 7‑day return of –6.9% and a 30‑day return of –13.5%, yet its year‑to‑date gain of 44.4% and 1‑year total shareholder return of 88.8% suggest the pullback may be a sentiment reset rather than a fundamental shift. Analysts question whether the decline signals cracks in the business or merely a temporary correction around an intact long‑term thesis.

What did this article say?

Glaukos (GKOS) has posted a 3.9% annualized outperformance versus the market over the last decade, translating to an average annual return of 17.45%. The company’s market cap stands at $10.58 billion. This historical performance underscores the firm’s ability to generate consistent shareholder value, though no new catalysts or guidance updates are disclosed.

What did this article say?

Glaukos (GKOS) insiders recently sold shares totaling $2.48 million, as disclosed in a new SEC filing. The sale involved multiple holdings, suggesting a modest divestment rather than a strategic shift. While the transaction size is notable, it does not indicate a fundamental change in company outlook or financial health. The move may prompt a brief reassessment of insider confidence but is unlikely to materially alter GKOS’s valuation at this time.

What did this article say?

Glaukos (GKOS) has satisfied the Minervini Trend Template and a high‑growth momentum screen, indicating a robust uptrend and strong relative performance. The company is near its 52‑week high and shows accelerating revenue and EPS growth, positioning it favorably against peers. These technical and fundamental signals suggest a bullish stance for the near term, though the magnitude of upside remains moderate.

What did this article say?

Glaukos (GKOS) has delivered a 15.09% annualized return over the past five years, outperforming the broader market and achieving an average yearly gain of 26.17%. The company’s market capitalization stands at $10.97 billion, reflecting sustained investor confidence. While the data highlights strong historical performance, it does not signal any immediate operational or financial changes that would materially alter the company’s outlook.

What did this article say?

BTIG analyst Ryan Zimmerman maintains a Buy rating on Glaukos (NYSE:GKOS) and raises the price target from $193 to $202. The upgrade reflects confidence in the company's ocular therapeutic pipeline and recent clinical milestones. The higher target suggests a bullish outlook for the stock.

What did this article say?

Glaukos announced its participation in the upcoming Wells Fargo Healthcare Conference, scheduled for [date]. The company will showcase its latest ocular therapeutic advancements and engage with industry stakeholders. This event offers a platform for investors to gain insights into pipeline progress and potential collaborations. The conference may influence market perception, but no immediate financial impact is expected.

Technical Analysis

Real-time indicators across multiple timeframes

41

NEUTRAL

Technical indicators reflect the latest computed signal mix for this timeframe.

Unlock full technicals

Create a free account to access more indicators and deeper timeframe data.

Institutional & Hedge Fund Ownership

1 tracked managers · $203.86M combined position · 0 adding, 0 trimming, 1 unchanged (latest 13F filings)

Manager	Trend	Shares Held	% of Co.	Position Value	Filed
Citadel Advisors LLC	• Hold	1,458,617	2.44%	$203.86M	2026-09-02

Q2 2026 flow:1.46M sh bought ($203.86M)0 sh sold ($0)net +1.46M sh (+$203.86M)